Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis
|
By LabMedica International staff writers Posted on 29 Apr 2016 |
Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
Latest Molecular Diagnostics News
- Genomic Screening Expands Detection of Treatable Conditions in Newborns
- Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants
- Pooled Sputum Testing Offers Lower-Cost Molecular Diagnosis for Tuberculosis
- Expanded Sequencing Panel Supports Myeloid Malignancy Variant Profiling
- Tumor Markers Help Predict Response to Less Intensive HER2+ Chemotherapy
- New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies
- Tumor-Informed ctDNA Test Shows Utility Across Gastrointestinal and Gynecologic Cancers
- New Molecular Testing Support to Strengthen Ebola Surveillance in DRC
- Functional Testing From Skin Biopsy Improves Detection of Mitochondrial Disease
- Blood Test Detects Molecular Signals of Early Liver Cancer Progression
- Breast Milk DNA Test Investigated for Early Breast Cancer Detection
- Blood-Based MRD Test Shows High Specificity in Colorectal Cancer Trials
- Blood-Based MRD Test Predicts Recurrence Risk After Melanoma Surgery
- Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
- Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
- Facilitated Cascade Program Increases Genetic Testing in Hereditary Cancer Families
Channels
Clinical Chemistry
view channel
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Study Questions Broad Fasting Requirements Before Routine Blood Tests
Routine blood testing is central to diagnosis, monitoring, and disease risk assessment. Many patients are still asked to fast for 8–12 hours before phlebotomy, even though the requirement was originally... Read more
Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed... Read more
Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis
Neonatal sepsis remains difficult to diagnose because early signs can resemble other newborn conditions. Diagnostic delays may increase the risk of complications, death, long-term adverse outcomes, and... Read moreMicrobiology
view channel
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read morePathology
view channel
AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
Ewing sarcoma is a rare malignant tumor that mainly affects children, adolescents, and young adults. It usually arises in bone but can also develop in soft tissue, where its microscopic appearance may... Read more
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more







